The "Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2019-2025" has been added to ResearchAndMarkets.com's offering.This report contains a comprehensive listing of option and ...

Ovintiv reports in U.S. dollars unless otherwise noted. Production, sales and reserves estimates are reported on an after-royalties basis, unless otherwise noted. Unless otherwise specified or the ...

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Landstar System, Inc. (“Landstar” or the “Compan ...

Broker Landstar System has delayed its first-quarter report as it further investigates what it says was fraud tied to an independent agent working under its freight forwarding operation. The post ...

Research and Development (R&D) Expenses: R&D expenses for the three months ended March 31, 2025, were $4.4 million, compared to $15.8 million for the same period in 2024. The decrease was due ...

risks and uncertainties related to the current unknown duration and severity of the COVID-19 pandemic and other risks detailed in the Company's periodic report filings with the Securities and Exchange ...

Baron Focused Growth Fund declined 7.95% in the first quarter of 2025. Who were the leaders and laggards? Click here to find ...

Introduction The global shift toward sustainability and climate-related financial disclosures has seen the International Financial Reporting Standards (IFRS) Foundation introduce two new ...

ST Xinchao announced that it was placed under investigation by the China Securities Regulatory Commission for failing to disclose its periodic report (2024 annual report) within the specified time ...

Continued Maintenance Investment to Drive Free Cash Flow; High-Graded Portfolio Bolsters Financial Resiliency Highlights: Generated cash from operating activities ...

Net Loss: For the first quarter of 2025, the Company generated a net loss attributable to its shareholders of $19.6 million, ...